{{Rsnum
|rsid=11141915
|Gene=DAPK1
|Chromosome=9
|position=87620879
|Orientation=plus
|GMAF=0.2718
|Gene_s=DAPK1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 58.4 | 38.1 | 3.5
| HCB | 38.5 | 43.7 | 17.8
| JPT | 39.8 | 49.6 | 10.6
| YRI | 42.5 | 44.5 | 13.0
| ASW | 57.9 | 36.8 | 5.3
| CHB | 38.5 | 43.7 | 17.8
| CHD | 40.7 | 41.7 | 17.6
| GIH | 39.0 | 42.0 | 19.0
| LWK | 53.6 | 37.3 | 9.1
| MEX | 77.6 | 20.7 | 1.7
| MKK | 45.2 | 44.5 | 10.3
| TSI | 71.3 | 26.7 | 2.0
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=22293537
|Trait=None
|Title=A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.
|RiskAllele=T
|Pval=0.000001
|OR=4.1000
|ORtxt=None
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}